Alector Enters Global License Agreement With Genentech

US biotech Alector has entered into an exclusive global licensing agreement with Genentech, according to The Pharma Letter. The publisher identified Genentech as a Roche subsidiary.

The announcement is a partnership event involving Alector and Genentech. The Pharma Letter reported the agreement as exclusive and global, linking the companies through a licensing arrangement.

Agreement reported by The Pharma Letter

The Pharma Letter said Alector entered the agreement with Genentech. The available report describes the arrangement as an exclusive global licensing agreement.

The supplied report does not specify the licensed asset or assets. It also does not provide details on financial terms, development responsibilities, commercialization activities, or other elements of the agreement.

For medical and biotech sales professionals, the reported transaction places Alector and Genentech in a newly announced licensing relationship. The agreement also involves Genentech in its capacity as a Roche subsidiary, as identified by the publisher.

Shares rose in pre-market activity

On news of the agreement, Alector’s shares leapt more than 60% to $2.90 in pre-market activity, The Pharma Letter reported.

The publisher presented the share movement alongside the licensing announcement. Its report connected the pre-market activity with news that Alector had entered the exclusive global agreement with Genentech.

No additional market information is included in the supplied evidence. The reported facts center on the agreement’s exclusive global scope, the companies involved, and the pre-market move in Alector shares.

Reported facts

• Alector is identified as a US biotech company.
• Genentech is identified as a Roche subsidiary.
• The agreement is described as an exclusive global licensing agreement.
• The Pharma Letter reported that Alector shares rose more than 60% to $2.90 in pre-market activity.